Last reviewed · How we verify
Gentamicin - three days
Gentamicin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, leading to bacterial cell death.
Gentamicin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, leading to bacterial cell death. Used for Bacterial infections in pediatric populations (specific indication unclear from limited context).
At a glance
| Generic name | Gentamicin - three days |
|---|---|
| Sponsor | Murdoch Childrens Research Institute |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Gentamicin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, disrupting accurate translation of mRNA and causing misreading of the genetic code. This results in production of non-functional proteins and ultimately bactericidal activity. The 'three days' formulation likely refers to a short-course dosing regimen, possibly for specific pediatric infections.
Approved indications
- Bacterial infections in pediatric populations (specific indication unclear from limited context)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Neuromuscular blockade
- Allergic reactions
Key clinical trials
- Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children (PHASE4)
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia (PHASE2, PHASE3)
- Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague (PHASE3)
- Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections (PHASE2)
- Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population
- Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) (PHASE1, PHASE2)
- Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy (PHASE2)
- The Amputation Surgical Site Infection Trial (ASSIT) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gentamicin - three days CI brief — competitive landscape report
- Gentamicin - three days updates RSS · CI watch RSS
- Murdoch Childrens Research Institute portfolio CI